Following a recent warning from the US Food and Drug Administration (FDA) on the safety of certain ultrasound contrast agents (UCAs) containing polyethylene glycol (PEG), the American Institute of Ultrasound in Medicine (AIUM) joins the International Contrast Ultrasound Society (ICUS) in issuing a statement to reassure physicians and their patients that ultrasound contrast agents remain safe and beneficial for most patients. 

Earlier, the FDA issued a notice that ultrasound contrast agents should not be administered to patients with known or suspected allergies to PEG. The FDA had become aware of immediate hypersensitivity reactions, including 11 cases of anaphylaxis and two deaths resulting from administration of those contrast media to patients with a reported history of PEG allergy.

The AIUM acknowledged the importance of the efforts by the FDA to communicate the potential risk of administering ultrasound contrast agents in patients who are sensitive to PEG, along with the modifications to product labeling. The statement from AIUM notes that reactions to PEG, although extremely rare, need to be considered alongside the clear benefits of contrast-enhanced ultrasound.